CoverageForm 410-K10-Q8-K13D13G13F

CI · Cigna Group - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · CI

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$68.49B-$69.75B$67.18B$65.50B-$63.69B$60.52B$57.26B-
Cost of Revenue$54.10B-$55.53B$53.27B$48.40B-$47.56B$44.49B$41.43B-
Gross Profit$14.39B-$14.22B$13.91B$17.10B-$16.13B$16.03B$15.82B-
R&D----------
SG&A$3.72B-$3.36B$3.43B$4.21B-$3.59B$3.68B$3.71B-
Total Operating Expenses----------
D&A$650.00M-$650.00M$738.00M$674.00M---$741.00M-
Operating Income$2.36B-$2.58B$2.31B$1.97B-$2.58B$2.41B$2.26B-
Interest Expense$357.00M-$363.00M$338.00M$362.00M-$380.00M$378.00M$369.00M-
Income Tax$409.00M-$322.00M$389.00M$239.00M-$367.00M$360.00M$291.00M-
Net Income$1.32B-$1.87B$1.53B$1.32B-$739.00M$1.55B($277.00M)-
EPS - Basic$6.30-$7.02$5.76$4.88-$2.65$5.51($0.97)-
EPS - Diluted$6.26-$6.98$5.71$4.85-$2.63$5.45($0.97)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$7.04B$7.68B$6.03B$4.33B$8.33B$7.55B$5.89B$6.79B$8.44B$7.82B
Accounts Receivable$26.61B$28.77B$31.71B$31.15B$26.93B$24.23B$27.85B$25.11B$20.56B$17.72B
Inventory$5.83B$7.34B$5.63B$5.97B$5.18B$6.69B$5.08B$5.17B$4.63B$5.64B
Accounts Payable$9.88B$10.66B$9.35B$9.94B$9.14B$9.29B$8.52B$9.28B$8.12B$8.55B
Current Assets$43.03B$47.81B$46.73B$44.72B$43.55B$48.87B$49.22B$46.22B$43.36B$37.35B
Total Assets$153.27B$157.92B$157.92B$151.65B$150.66B$155.88B$157.64B$155.45B$153.12B$152.76B
Current Liabilities$52.61B$56.34B$56.45B$56.78B$55.74B$57.98B$57.06B$55.37B$51.98B$48.72B
Long-term Debt----------
Total Liabilities$110.82B$116.05B$115.91B$111.22B$110.24B$114.64B$115.34B$113.92B$111.77B$106.41B
Stockholders' Equity$42.21B$41.71B$41.80B$40.21B$40.23B$41.03B$42.09B$41.33B$41.18B$46.22B
Retained Earnings$49.11B$47.87B$47.03B$45.56B$44.43B$43.52B$42.48B$42.13B$40.98B$41.65B

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow$1.13B---$1.92B---$4.84B-
Investing Cash Flow($637.00M)---$1.20B---($495.00M)-
Financing Cash Flow($1.14B)---($3.68B)---($2.53B)-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin21.0%-20.4%20.7%26.1%-25.3%26.5%27.6%-
Operating margin3.4%-3.7%3.4%3.0%-4.0%4.0%3.9%-
EBITDA margin4.4%-4.6%4.5%4.0%---5.2%-
Net margin1.9%-2.7%2.3%2.0%-1.2%2.6%-0.5%-
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue5.4%-4.8%5.1%6.4%-5.6%6.1%6.5%-
Effective tax rate23.6%-14.7%20.2%15.3%-33.2%18.9%2078.6%-
Return on assets0.9%-1.2%1.0%0.9%-0.5%1.0%-0.2%-
Return on equity3.1%-4.5%3.8%3.3%-1.8%3.7%-0.7%-
Return on invested capital----------
Liquidity
Current ratio0.820.850.830.790.780.840.860.830.830.77
Quick ratio0.710.720.730.680.690.730.770.740.750.65
Cash ratio0.130.140.110.080.150.130.100.120.160.16
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage6.6x-7.1x6.8x5.4x-6.8x6.4x6.1x-
Equity multiplier3.633.793.783.773.753.803.743.763.723.30
Liabilities / Assets0.720.730.730.730.730.740.730.730.730.70
Efficiency
Asset turnover0.45-0.440.440.43-0.400.390.37-
Inventory turnover9.28-9.868.939.35-9.368.608.95-
Days sales outstanding142d-166d169d150d-160d151d131d-
Days inventory outstanding39d-37d41d39d-39d42d41d-
Days payable outstanding67d-61d68d69d-65d76d72d-
Cash conversion cycle114d-142d142d120d-133d118d100d-
Valuation
P / E42.6x-41.3x57.9x67.8x-131.7x60.7x--
P / B1.7x-1.8x2.2x2.2x-2.3x2.3x2.5x-
P / S1.0x-1.1x1.3x1.4x-1.5x1.6x1.8x-
EV / EBITDA21.1x-22.0x27.7x30.8x---31.9x-
Growth
Revenue growth (YoY)4.6%-9.5%11.0%14.4%-29.9%24.6%23.1%-
Revenue CAGR (3y)13.8%-15.5%13.9%14.2%-12.9%12.0%11.8%-
Revenue CAGR (5y)10.8%-11.2%11.3%11.2%-10.6%9.3%8.6%-
Gross profit growth (YoY)-15.8%--11.8%-13.2%8.1%-4.7%5.9%5.1%-
Operating income growth (YoY)19.6%-0.1%-4.4%-12.6%-15.0%8.6%12.0%-
Net income growth (YoY)0.0%-152.8%-1.0%---47.5%6.0%--
EPS growth (YoY)29.1%-165.4%4.8%---44.5%10.8%--
EPS CAGR (3y)13.9%--8.0%5.2%9.6%--18.2%8.6%--
EPS CAGR (5y)13.7%-13.1%3.8%9.0%--5.9%8.1%--
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)4.9%1.7%-0.7%-2.7%-2.3%-11.2%-7.9%-9.1%-7.5%3.0%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$283.04B total
Evernorth$234.95B · 83.0%
Cigna Healthcare$47.41B · 16.8%
All Other Segments$674.00M · 0.2%

Product / service

$469.10B total
Product$216.67B · 46.2%
Network Pharmacy$125.57B · 26.8%
Home Delivery And Specialty$80.49B · 17.2%
Service$16.92B · 3.6%
Service Fees And Other Revenues$15.42B · 3.3%
Other Pharmacy$13.33B · 2.8%
Service Other$696.00M · 0.1%

Peer comparison

Same SIC group: Hospital & Medical Service Plans

CompanyRevenue (last FY)Net marginROE
UNH$447.57B2.7%12.0%
TRUP$1.44B1.4%5.1%
CNC$194.78B-3.4%-33.4%
ALHC$3.95B-0.0%-0.4%
CLOV$1.92B-4.4%-27.7%

Comparing Cigna Group against the 5 most active filers in the same SIC group.

Dividends

$4.58/share trailing 12 months · -21.3% YoY

Ex-datePer share
Mar 5, 2026$1.5600
Dec 4, 2025$1.5100
Sep 4, 2025$1.5100
Jun 3, 2025$1.5100
Mar 5, 2025$1.5100
Dec 4, 2024$1.4000
Sep 4, 2024$1.4000
Jun 4, 2024$1.4000
Mar 5, 2024$1.4000
Dec 5, 2023$1.2300
Sep 5, 2023$1.2300
Jun 6, 2023$1.2300
Mar 7, 2023$1.2300
Dec 5, 2022$1.1200
Sep 6, 2022$1.1200
Jun 7, 2022$1.1200
Mar 8, 2022$1.1200
Dec 6, 2021$1.0000
Sep 7, 2021$1.0000
Jun 7, 2021$1.0000
Mar 9, 2021$1.0000
Mar 9, 2020$0.0400
Mar 8, 2019$0.0400
Mar 9, 2018$0.0400